Using Non-targeted Therapies in Targeted Lung Cancer Populations

42
Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D. September 6, 2014

description

Using Non-targeted Therapies in Targeted Lung Cancer Populations. Nathan Pennell, M.D., Ph.D. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy - PowerPoint PPT Presentation

Transcript of Using Non-targeted Therapies in Targeted Lung Cancer Populations

Page 1: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Using Non-targeted Therapies in Targeted Lung Cancer Populations

Nathan Pennell, M.D., Ph.D.September 6, 2014

Page 2: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Objectives

• Discuss the role of chemotherapy in molecularly defined populations

• Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy

• Do immune checkpoint inhibitors (anti-PD-1/PDL-1) have a role in treatment of molecularly defined populations?

2

Page 3: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Why would anyone use chemotherapy in an EGFR

mutant or ALK+ lung cancer patient?

3

Page 4: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Case 1 – 24M with ALK+ NSCLC

• Presented in 2011 with extensive adenopathy and malignant effusions

• Started crizotinib with CR

4

September 2011 January 2012

Page 5: Using Non-targeted Therapies in Targeted Lung Cancer Populations

EML4-ALK Translocations in NSCLC

EML4-ALK frequency:

~4% (64/1709)

Primarily lung adenocarcinoma

EML4-ALK frequency:

~4% (64/1709)

Primarily lung adenocarcinoma

Soda et al., Nature 448: 561-566, 2007 Soda et al., Nature 448: 561-566, 2007

Page 6: Using Non-targeted Therapies in Targeted Lung Cancer Populations

First line chemotherapy versus crizotinib in ALK+ NSCLC (Mok ASCO 2014)

Page 7: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Case 1 – 24M with ALK+ NSCLC

• Presented in 2011 with extensive adenopathy and malignant effusions

• Crizotinib with CR • 8 months until progression• Ceritinib (on trial as LDK378) CR • 6 months until progression

7

Page 8: Using Non-targeted Therapies in Targeted Lung Cancer Populations

What are the options?

• Third generation TKI?

• Clinical trial, i.e. HSP90?

• How about chemotherapy?

8

Page 9: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Chemotherapy vs. BSC: Meta-analysis summary

Chemo Hazard Ratio MST (m) 1-yr OS (%)

Alkylating 1.26 -1 - 6

Vinca/VP16 0.87 +1 + 4

Cisplatin 0.73 +2 +10

BMJ 311: 899, 1995

Page 10: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Platinum doublet chemotherapy in nonsquamous patients

Scagliotti GV et al, JCO 2008;26(21):3543-51

Page 11: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Case 1 – 24M with ALK+ NSCLC

• Presented in 2011 with extensive adenopathy and malignant effusions

• Crizotinib with CR • 8 months until progression• Ceritinib (on trial as LDK378) CR • 6 months until progression• Started carboplatin, pemetrexed, and

bevacizumab followed by pem/bev maintenance in late 2012…

11

Page 12: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Maintenance pemetrexed and bevacizumab

December 2012 March 2013

Page 13: Using Non-targeted Therapies in Targeted Lung Cancer Populations

June 2014 – 18 months on chemo

13

Page 14: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Case 2 – 36 year old woman with hip pain August 2008

• Scans showed destructive bone lesion in pelvis

• Biopsy showed lung adenocarcinoma

• Started on carboplatin, paclitaxel, bevacizumab in late 2008

• Progressed in summer 2009, started pemetrexed

14

Page 15: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Case 2 – Now 42 year old woman without hip pain

• On intermittent pemetrexed until 2012 (2.5 years) when test showed she was ALK+

• 4 treatment breaks ranging from 6-12 months

• No ALK directed therapy yet!

June 2014

Page 16: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Pemetrexed may have significant benefit for ALK+ pts

• 65 ALK+ patients response to chemotherapy retrospectively analyzed1

• ORR to pem 34% (9% in unselected NSCLC pts2)

161Lee et al., Lung Cancer 2013, 79(1); 2Hanna et al., JCO 2004

Page 17: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Pemetrexed may have significant benefit for ALK+ pts

17Berge et al., Clin Lung Cancer. Nov 2013; 14(6): 636–643.

Page 18: Using Non-targeted Therapies in Targeted Lung Cancer Populations
Page 19: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Erlotinib vs. CT in Advanced NSCLC Patients With EGFR Mutations: Interim Results of the European Erlotinib Versus CT

(EURTAC) Phase III Randomized Trial

PF

S p

rob

abili

ty

Erlotinib (n=86) Chemotherapy (n=87)

HR=0.37 (0.25–0.54)Log-rank p<0.0001

Time (months)

0 3 6 9 12 15 18 21 24 27 30 33

Data cut-off: 26 Jan 2011

1.0

0.8

0.6

0.4

0.2

09.75.2

Slide courtesy of Tony Mok, ASCO discussant. Rosell R, et al. J Clin Oncol. 2011;29(suppl): abstr# 7503.

Page 20: Using Non-targeted Therapies in Targeted Lung Cancer Populations

EGFR Mutation+ NSCLC and Erlotinib

Day 0 4 months

25 months

Page 21: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Chemotherapy in unselected pts

21Schiller et al., N Engl J Med 2002;346:92-8.)

Page 22: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Chemotherapy may be more effective in EGFR mutants than in wt patients

Study Response RateIPASS 71% vs. 47%OPTIMAL 83% vs. 36%NEJ 002 74% vs. 31%WJTOG 3405 62% vs. 31%EURTAC 58% vs. 15%

22Chemo in BOLD

Page 23: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Pooled analysis of clinical outcome for EGFR TKI treated ‐patients with EGFR mutation positive NSCLC‐

Journal of Cellular and Molecular Medicine6 AUG 2014 DOI: 10.1111/jcmm.12278http://onlinelibrary.wiley.com/doi/10.1111/jcmm.12278/full#jcmm12278-fig-0002

Page 24: Using Non-targeted Therapies in Targeted Lung Cancer Populations

24

Conclusion: Chemo is effective in EGFR mutant and ALK+ NSCLC

• Chemotherapy is effective and should be considered in patients when TKIs fail

JJ (CHOP calendar) http://mbvshl.blogspot.com/2013/02/round-9-looking-good-billy-ray-feeling.html

Page 25: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Can we improve on the effectiveness of TKIs up front by adding non-targeted agents?

Chemotherapy? Bevacizumab?(anti-VEGF)

25

Page 26: Using Non-targeted Therapies in Targeted Lung Cancer Populations

EGFR TKIs + Chemotherapy = Not better than chemo alone?

• 4 large phase 3 trials with gefitinib (INTACT 1/2) and erlotinib (TRIBUTE/TALENT)

• All showed no evidence that chemo + TKI was better in unselected NSCLC patients

• But what about EGFR mutation+ patients?

26

Page 27: Using Non-targeted Therapies in Targeted Lung Cancer Populations

FASTACT 2: Chemotherapy plus erlotinib versus chemotherapy

27Wu et al., Lancet Oncol 2013; 14: 777–86

Median PFS 16.8 v 6.9 months

Page 28: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Chemotherapy plus TKI in EGFR mutation+ pts

• Promising signs but need randomized trial of chemo plus TKI versus TKI alone

• Chinese study ongoing of carboplatin + pemetrexed (CP), CP + gefitinib, and gefitinib (NCT02148380)

28

Page 29: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Does adding bevacizumab to TKIs improve efficacy?

• BeTa phase 3 trial of erlotinib +/- bev

• Not significant but promising trend towards better survival

29Herbst et al., Lancet 2011 May 28;377(9780):1846-54

Page 30: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Study design

Presented By Terufumi Kato at 2014 ASCO Annual Meeting

- Phase 2 trial

Page 31: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Primary endpoint: PFS by independent review

Presented By Terufumi Kato at 2014 ASCO Annual Meeting

Page 32: Using Non-targeted Therapies in Targeted Lung Cancer Populations

PFS by EGFR mutation type

Presented By Terufumi Kato at 2014 ASCO Annual Meeting

Page 33: Using Non-targeted Therapies in Targeted Lung Cancer Populations

AEs (incidence >20%)

Presented By Terufumi Kato at 2014 ASCO Annual Meeting

Page 34: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Conclusions: Adding to TKIs

• Chemotherapy plus EGFR TKI results in a promising PFS compared to chemo

• Bev plus erlotinib also results in a promising PFS compared to TKI alone

• Adding chemo or bev to the TKI adds a non-trivial amount of side effects and risk (and cost)

• Evidence for improved survival needed before it becomes SOC compared to TKI alone

34

Page 35: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Immunotherapy: i.e. Checkpoint inhibitors (anti-PD-1 and PDL-1)?

35

Page 36: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Checkpoint Inhibitors in Development in NSCLCResponse rates consistently ~20%

Page 37: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Duration of Response and Overall Survival with Nivolumab in Pretreated Advanced NSCLC

Presented By Scott Gettinger at 2014 ASCO Annual Meeting

Page 38: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Checkpoint Inhibitors in EGFR mutant population?

• In mouse models of EGFR mutant NSCLC PDL-1 was high and anti-PD1 was quite effective1

• In a cohort of 56 EGFR mutant NSCLCs, 71% were PDL-1 positive (compared to about 50% in unselected NSCLC)2

38Akbay et al., Can Disc 2013, 3, 1355; D’Incecco et al., ELCC 2914

PDL-1

Page 39: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Checkpoint Inhibitors in EGFR mutant population?

• In a small phase 2 trial, 20 pts with EGFR mutant NSCLC with AR were treated with nivolumab + erlotinib with ORR of 15%2

39Rizvi et al., ASCO Proc 2014, Abst,

Page 40: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Conclusions: Immunotherapy

• Too early to say whether checkpoint inhibitors will play a more significant role in EGFR mutant and ALK+ NSCLC treatment, BUT

• No reason to think they won’t be at least as effective as in unselected patients!

40

Page 41: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Take Home Points

• While TKIs are the most effective treatment for genetically defined NSCLC pts, chemotherapy can be an effective alternative

• Adding chemotherapy or bevacizumab to TKIs may make TKIs more effective, but the jury is still out

• Immunotherapy is enormously promising in all types of lung cancer!

41

Page 42: Using Non-targeted Therapies in Targeted Lung Cancer Populations

Thank You!